Page 6 - Priority Review News Today

Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These...

Media Update New data presented at ATS demonstrate Sanofis leadership in advancing potential new therapies for patients with immune-mediated respiratory...

The U.S. Food and Drug Administration recently approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. 

EQS-News: Heidelberg Pharma AG / Key word: Quarterly / Interim Statement Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 25.04.2024 /...

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...

Sales Reflect Continued Strong Growth in Oncology and Vaccines Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange,...

Performance Reflects Execution and Actions to Strengthen the Companys Long-Term Growth Profile First Quarter Revenues were $11.9 Billion, increasing 5% Growth Portfolio Revenues were $4.8...

The U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

GSK has received the US Food and Drug Administration’s (FDA) acceptance for its supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) along with standard-of-care chemotherapy (carboplatin and paclitaxel). 

Follow-up Scans Show Continued Stable Disease in First Patient Cohort Company to Apply for FDA Fast Track Designation ...